Fampridine sustained-release

Drug Profile

Fampridine sustained-release

Alternative Names: 4-Aminopyridine modified release - Acorda Therapeutics; 4-AP - Acorda Therapeutics; Ampyra; BIIB 041; Dalfampridine ER; Dalfampridine extended-release; Dalfampridine QD; Dalfampridine-SR; EL 970; Fampridine ER; Fampridine extended-release; Fampridine-PR; Fampridine-SR; Fampyra; Neurelan; PR-FAM

Latest Information Update: 31 May 2017

Price : $50

At a glance

  • Originator Elan Drug Technologies
  • Developer Acorda Therapeutics; Biogen; Kessler Foundation; University of California at Los Angeles; University of Florida; University of Miami
  • Class Aminopyridines; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase III Ataxia
  • Phase II Spinal cord injuries; Spinocerebellar degeneration
  • Phase I/II Parkinson's disease
  • No development reported Cerebral palsy
  • Discontinued Neurological disorders

Most Recent Events

  • 24 May 2017 European Medicine Agency approves fampridine SR for walking ability in patients with Multiple sclerosis in European union
  • 31 Mar 2017 The United States District Court of Delaware upheld patent related to formulation of dalfampridine extended release tablets
  • 09 Mar 2017 The USPTO’s Patent Trials and Appeal Board (PTAB) uphelds four patents related to use of dalfampridine extended release tablets
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top